We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28%) patients were seizure free, 42 (30%) responders, 42 (30%) immodified and 18 (12%) patients were worsened. After 1 year 99 (71%) patients were till in the study. 22 (14%) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.
|Translated title of the contribution||Efficacy and safety of Levetiracetam as add-on therapy in patients with refractory partial epilepsy: A long-term, open-label, prospective study|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - Jul 2004|
ASJC Scopus subject areas
- Clinical Neurology